Treatment results of chemoradiotherapy with 5-FU/CDGP for head and neck cancer

Kengo Himei, Norihisa Katayama, Mitsuhiro Takemoto, Masahiro Kuroda, Susumu Kanazawa, Shigenobu Nomiya, Tomoo Onoda, Susumu Tominaga

Research output: Contribution to journalArticle

Abstract

We investigated the safety and efficacy of alternative and concurrent chemoradiotherapy with 5-FU/CDGP for head and neck cancer. From January 2003 to August 2005, 19 patients with head and neck squamous cell carcinoma were treated in our institution. Alternative chemoradiotherapy (ACRT) was performed for 8 cases of nasopharyngeal cancer. Concurrent chemoradiotherapy (CCRT) was performed for 11 cases of other head and neck cancer. Median total dose of radiotherapy was 63Gy. ACRT consisted of 5-FU at a dose of 500mg/m2 on days 1-5 and 28-32 and CDGP at a dose of 60mg/m2 on days 6 and 33. CCRT consisted of 5-FU at a dose of 500mg/m2 on days 1-4 and 28-31 and CDGP at a dose of 60mg/m2 on days 5 and 32. Median follow-up periods was 13 months. CR+PR was admitted in five cases (63%) with ACRT, and in 9 cases (82%) with CCRT. Non-hematological adverse effects of grade 3 were admitted in eight cases (100%) of ACRT, and in 9 cases (82%) of CCRT. Chemoradiotherapy attained good results and non-hematological adverse effects were able to be managed by preserved treatment.

Original languageEnglish
Pages (from-to)378-383
Number of pages6
JournalToukeibu Gan
Volume32
Issue number3
DOIs
Publication statusPublished - 2006

Fingerprint

Chemoradiotherapy
Head and Neck Neoplasms
Fluorouracil
Therapeutics
Nasopharyngeal Neoplasms
Radiotherapy
Safety

Keywords

  • alternative chemoradiotherapy
  • concurrent chemoradiotherapy
  • head and neck cancer
  • nasopharyngeal cancer

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Oncology

Cite this

Treatment results of chemoradiotherapy with 5-FU/CDGP for head and neck cancer. / Himei, Kengo; Katayama, Norihisa; Takemoto, Mitsuhiro; Kuroda, Masahiro; Kanazawa, Susumu; Nomiya, Shigenobu; Onoda, Tomoo; Tominaga, Susumu.

In: Toukeibu Gan, Vol. 32, No. 3, 2006, p. 378-383.

Research output: Contribution to journalArticle

Himei, Kengo ; Katayama, Norihisa ; Takemoto, Mitsuhiro ; Kuroda, Masahiro ; Kanazawa, Susumu ; Nomiya, Shigenobu ; Onoda, Tomoo ; Tominaga, Susumu. / Treatment results of chemoradiotherapy with 5-FU/CDGP for head and neck cancer. In: Toukeibu Gan. 2006 ; Vol. 32, No. 3. pp. 378-383.
@article{a39a52518f824a39be7b645f77515178,
title = "Treatment results of chemoradiotherapy with 5-FU/CDGP for head and neck cancer",
abstract = "We investigated the safety and efficacy of alternative and concurrent chemoradiotherapy with 5-FU/CDGP for head and neck cancer. From January 2003 to August 2005, 19 patients with head and neck squamous cell carcinoma were treated in our institution. Alternative chemoradiotherapy (ACRT) was performed for 8 cases of nasopharyngeal cancer. Concurrent chemoradiotherapy (CCRT) was performed for 11 cases of other head and neck cancer. Median total dose of radiotherapy was 63Gy. ACRT consisted of 5-FU at a dose of 500mg/m2 on days 1-5 and 28-32 and CDGP at a dose of 60mg/m2 on days 6 and 33. CCRT consisted of 5-FU at a dose of 500mg/m2 on days 1-4 and 28-31 and CDGP at a dose of 60mg/m2 on days 5 and 32. Median follow-up periods was 13 months. CR+PR was admitted in five cases (63{\%}) with ACRT, and in 9 cases (82{\%}) with CCRT. Non-hematological adverse effects of grade 3 were admitted in eight cases (100{\%}) of ACRT, and in 9 cases (82{\%}) of CCRT. Chemoradiotherapy attained good results and non-hematological adverse effects were able to be managed by preserved treatment.",
keywords = "alternative chemoradiotherapy, concurrent chemoradiotherapy, head and neck cancer, nasopharyngeal cancer",
author = "Kengo Himei and Norihisa Katayama and Mitsuhiro Takemoto and Masahiro Kuroda and Susumu Kanazawa and Shigenobu Nomiya and Tomoo Onoda and Susumu Tominaga",
year = "2006",
doi = "10.5981/jjhnc.32.378",
language = "English",
volume = "32",
pages = "378--383",
journal = "Japanese Journal of Head and Neck Cancer",
issn = "1349-5747",
publisher = "Nihon Tokeibu Gan Gakkai",
number = "3",

}

TY - JOUR

T1 - Treatment results of chemoradiotherapy with 5-FU/CDGP for head and neck cancer

AU - Himei, Kengo

AU - Katayama, Norihisa

AU - Takemoto, Mitsuhiro

AU - Kuroda, Masahiro

AU - Kanazawa, Susumu

AU - Nomiya, Shigenobu

AU - Onoda, Tomoo

AU - Tominaga, Susumu

PY - 2006

Y1 - 2006

N2 - We investigated the safety and efficacy of alternative and concurrent chemoradiotherapy with 5-FU/CDGP for head and neck cancer. From January 2003 to August 2005, 19 patients with head and neck squamous cell carcinoma were treated in our institution. Alternative chemoradiotherapy (ACRT) was performed for 8 cases of nasopharyngeal cancer. Concurrent chemoradiotherapy (CCRT) was performed for 11 cases of other head and neck cancer. Median total dose of radiotherapy was 63Gy. ACRT consisted of 5-FU at a dose of 500mg/m2 on days 1-5 and 28-32 and CDGP at a dose of 60mg/m2 on days 6 and 33. CCRT consisted of 5-FU at a dose of 500mg/m2 on days 1-4 and 28-31 and CDGP at a dose of 60mg/m2 on days 5 and 32. Median follow-up periods was 13 months. CR+PR was admitted in five cases (63%) with ACRT, and in 9 cases (82%) with CCRT. Non-hematological adverse effects of grade 3 were admitted in eight cases (100%) of ACRT, and in 9 cases (82%) of CCRT. Chemoradiotherapy attained good results and non-hematological adverse effects were able to be managed by preserved treatment.

AB - We investigated the safety and efficacy of alternative and concurrent chemoradiotherapy with 5-FU/CDGP for head and neck cancer. From January 2003 to August 2005, 19 patients with head and neck squamous cell carcinoma were treated in our institution. Alternative chemoradiotherapy (ACRT) was performed for 8 cases of nasopharyngeal cancer. Concurrent chemoradiotherapy (CCRT) was performed for 11 cases of other head and neck cancer. Median total dose of radiotherapy was 63Gy. ACRT consisted of 5-FU at a dose of 500mg/m2 on days 1-5 and 28-32 and CDGP at a dose of 60mg/m2 on days 6 and 33. CCRT consisted of 5-FU at a dose of 500mg/m2 on days 1-4 and 28-31 and CDGP at a dose of 60mg/m2 on days 5 and 32. Median follow-up periods was 13 months. CR+PR was admitted in five cases (63%) with ACRT, and in 9 cases (82%) with CCRT. Non-hematological adverse effects of grade 3 were admitted in eight cases (100%) of ACRT, and in 9 cases (82%) of CCRT. Chemoradiotherapy attained good results and non-hematological adverse effects were able to be managed by preserved treatment.

KW - alternative chemoradiotherapy

KW - concurrent chemoradiotherapy

KW - head and neck cancer

KW - nasopharyngeal cancer

UR - http://www.scopus.com/inward/record.url?scp=85009580332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009580332&partnerID=8YFLogxK

U2 - 10.5981/jjhnc.32.378

DO - 10.5981/jjhnc.32.378

M3 - Article

AN - SCOPUS:85009580332

VL - 32

SP - 378

EP - 383

JO - Japanese Journal of Head and Neck Cancer

JF - Japanese Journal of Head and Neck Cancer

SN - 1349-5747

IS - 3

ER -